Ian has been covering a broad range of topics across the Japanese and Asian pharma industry, including corporate, M&A, R&D, pricing and policy developments, since 1988. After a stint as Tokyo-based Japan and Asia editor for Scrip, in 2014 he became managing editor of PharmAsia News (now part of Scrip/Pink Sheet). In his current position, he directs regional coverage for Scrip and Pink Sheet and manages a multinational, on-the-ground team. Ian is a recipient of multiple internal and external awards and a regular participant in APAC conferences, webinars and events, and produces regular podcasts. He has spent the majority of his life in Asia, having grown up in Hong Kong, and enjoys cycling and music.
Latest from Ian Haydock
In this week's episode: key themes for JPM; 2024 launches a breakout for liver disease; obesity drug readouts this year; IgA nephropathy snapshot; and only half of 2024 launches were from big pharma.
The head of Chugai's new $200m venture capital fund talks to Scrip about its investment priorities.
Asia-Pacific continues to solidify its position as a key location for clinical trials, with China in particular dominating such activity in the region, and increasingly globally, a Citeline White Paper shows.
In this week's episode: Pfizer’s 2025 policy outlook; made in China blockbusters elusive; Vertex’s pain plans; Q3’s top 10 drugs; and sickle cell disease at ASH.
Plus deals involving Hangzhou DAC/Aadi, Astellas/Sangamo, Kyorin/Bayer, Eisai/Newron, Lupin/Boehringer Ingelheim, Asahi Kasei/Chiome and more.
Japanese major highlights at R&D Day key late-stage pipeline assets set to be filed for approval over the next few years, which it says have a combined peak sales potential of $10-20bn, and which could help it weather the expiry of current blockbuster Entyvio.